A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
Eisai Inc.
Eisai Inc.
Coherus Oncology, Inc.
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Zhejiang Provincial People's Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Rutgers, The State University of New Jersey
Sanofi
Exelixis
Fudan University
Merck Sharp & Dohme LLC
Fujian Medical University
University of Alabama at Birmingham
Biotech Pharmaceutical Co., Ltd.
University of Alabama at Birmingham
Institut Sainte Catherine
The First Affiliated Hospital of Zhengzhou University
National Taiwan University Hospital
National Taiwan University Hospital
Xintian Pharmaceutical
Kyowa Kirin Co., Ltd.
Saint Petersburg State University, Russia
Nanfang Hospital, Southern Medical University
University Medical Center Groningen
Assistance Publique Hopitaux De Marseille
Universitätsklinikum Hamburg-Eppendorf
National Medical Research Radiological Centre of the Ministry of Health of Russia
Montefiore Medical Center
Aziende Chimiche Riunite Angelini Francesco S.p.A
Medstar Health Research Institute
University of Heidelberg Medical Center
Qianfoshan Hospital
Zhongshan Hospital Xiamen University
Emory University
DHR Health Institute for Research and Development
Federal University of Minas Gerais
Region Skane
Tianjin Medical University Cancer Institute and Hospital
University of Texas Southwestern Medical Center
Centre Hospitalier Universitaire de la Guadeloupe
Sun Yat-sen University
The First Affiliated Hospital of Dalian Medical University
Augusta University
Medical University Innsbruck
Mercy Research
University Health Network, Toronto
Fundacion Clinic per a la Recerca Biomédica
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Central Hospital, Nancy, France
Ain Shams University